Artemisinin dimers can target heme-dependent IDO1 for degradation, reducing tumor KYN levels by approximately 75% and synergizing with anti-PD-1 therapy (Stockwin et al., 2009; Berdelle et al., 2011; Xia et al., 2025). The gene discussed is IDO1; the disease is neoplasm.